Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On August 5, 2025, the National Company Law Tribunal in Hyderabad approved the voluntary liquidation of Dr. Reddy’s Laboratories’ wholly-owned subsidiary, Imperial Owners and Land Possessions Private Limited. The dissolution of Imperial, which is not a material subsidiary, will not significantly impact Dr. Reddy’s consolidated financials.
The most recent analyst rating on (RDY) stock is a Buy with a $18.30 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
Dr Reddy’s Laboratories exhibits strong financial fundamentals with consistent revenue and profit growth. However, bearish technical indicators and balanced earnings call sentiment due to challenges in the U.S. market and increased expenses weigh down the overall score. The valuation is reasonable, providing moderate income potential.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It is involved in the manufacturing and marketing of a wide range of pharmaceutical products and services, focusing on generic medications and active pharmaceutical ingredients. The company is listed on major stock exchanges, including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
Average Trading Volume: 1,599,105
Technical Sentiment Signal: Hold
Current Market Cap: $11.41B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.